Results 181 to 190 of about 594,928 (357)
Molecular evolution of viruses; ‘trees’, ‘clocks’ and ‘modules’
Adrian J. Gibbs
openalex +1 more source
Monitoring and redirecting virus evolution
Gonzalo Moratorio, Marco Vignuzzi
openaire +5 more sources
ABSTRACT Background Managing long COVID in people with multiple sclerosis and related disorders (pwMSRD) is complex due to overlapping symptoms. To address evidence gaps, we evaluated long COVID susceptibility in pwMSRD versus controls and its associations with multi‐domain function and disability.
Chen Hu +15 more
wiley +1 more source
Antigenicity and evolution amongst recent influenza viruses of HIN1 subtype
F. Lucy Raymond +4 more
openalex +2 more sources
Origin and Rapid Evolution of a Novel Murine Erythroleukemia Virus of the Spleen Focus-Forming Virus Family [PDF]
Maureen E. Hoatlin +4 more
openalex +1 more source
ABSTRACT Objective Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which ...
Regina Berkovich +10 more
wiley +1 more source
Defects in plant immunity modulate the rates and patterns of RNA virus evolution. [PDF]
Navarro R +7 more
europepmc +1 more source
Biological and Genetic Evolution of the Nucleoprotein Gene of Human Influenza A Viruses
Axel Altmüller +2 more
openalex +1 more source
SNUPN‐Related Muscular Dystrophy: Novel Phenotypic, Pathological and Functional Protein Insights
ABSTRACT Objective SNUPN‐related muscular dystrophy or LGMDR29 is a new entity that covers from a congenital or childhood onset pure muscular dystrophy to more complex phenotypes combining neurodevelopmental features, cataracts, or spinocerebellar ataxia. So far, 12 different variants have been described.
Nuria Muelas +18 more
wiley +1 more source
Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. [PDF]
Lee KM, Lin SJ, Wu CJ, Kuo RL.
europepmc +1 more source

